Suppr超能文献

经皮内镜胃造口术(PEG)中抗生素预防的新方法:随机对照试验。

Novel approach to antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): randomised controlled trial.

机构信息

Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 76 Stockholm, Sweden.

出版信息

BMJ. 2010 Jul 2;341:c3115. doi: 10.1136/bmj.c3115.

Abstract

OBJECTIVE

To evaluate a new and simpler strategy of antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG).

DESIGN

Single centre, two arm, randomised, controlled, double blind clinical trial.

SETTING

Endoscopy unit in Karolinska University Hospital, Stockholm, Sweden, between 3 June 2005 and 31 October 2009.

PARTICIPANTS

234 patients with an indication for PEG who gave informed consent to participate.

INTERVENTION

A single 20 ml dose of the oral solution of sulfamethoxazole and trimethoprim (also known as co-trimoxazole or Bactrim; F Hoffmann-La Roche Ltd, Basel, Switzerland) deposited in the PEG catheter immediately after insertion. The control group received standard prophylaxis consisting of a single intravenous dose of 1.5 g cefuroxime (Zinacef; GlaxoSmithKline, London) administered before insertion of the PEG tube.

MAIN OUTCOME MEASURE

Primary outcome was the occurrence of clinically evident wound infection within 14 days after insertion of the PEG catheter. Secondary outcomes were positive bacterial culture and blood tests (highly sensitive C reactive protein and white blood cell count). All randomised patients were included in an intention to treat analysis.

RESULTS

Of the 234 patients included in this study, 116 were randomly assigned to co-trimoxazole and 118 to cefuroxime. At follow-up 7-14 days after insertion of the PEG catheter, wound infection was found in 10 (8.6%) patients in the co-trimoxazole group and 14 (11.9%) in the cefuroxime group, which corresponds to a percentage point difference of -3.3% (95% confidence interval -10.9% to 4.5%). The per protocol analysis, which comprised 100 patients in each group, gave similar results-10% and 13% infection in the co-trimoxazole and cefuroxime groups, respectively (percentage point difference -3.0%, 95% CI -11.8% to 5.8%). Both these analyses indicate non-inferiority of co-trimoxazole compared with cefuroxime because the upper bounds of the confidence intervals are lower than the pre-determined non-inferiority margin of 15%. Analyses of the secondary outcomes supported this finding.

CONCLUSION

20 ml of co-trimoxazole solution deposited in a newly inserted PEG catheter is at least as effective as cefuroxime prophylaxis given intravenously before PEG at preventing wound infections in patients undergoing PEG. Trial registration Current Controlled Trials ISRCTN18677736.

摘要

目的

评估经皮内镜胃造口术(PEG)中一种新的、更简单的抗生素预防策略。

设计

单中心、两臂、随机、对照、双盲临床试验。

地点

瑞典斯德哥尔摩卡罗林斯卡大学医院内镜科,2005 年 6 月 3 日至 2009 年 10 月 31 日。

参与者

234 名有 PEG 适应证并同意参与的患者。

干预措施

将 20 毫升磺胺甲恶唑和甲氧苄啶(也称为复方新诺明或 Bactrim;罗氏公司,巴塞尔,瑞士)口服溶液单剂量注入新插入的 PEG 导管中。对照组接受标准预防,即在插入 PEG 管前给予单次静脉注射 1.5 克头孢呋辛(头孢呋辛;葛兰素史克公司,伦敦)。

主要观察指标

主要结局是 PEG 导管插入后 14 天内出现临床明显的伤口感染。次要结局是阳性细菌培养和血液检查(高敏 C 反应蛋白和白细胞计数)。所有随机患者均进行意向治疗分析。

结果

本研究共纳入 234 例患者,其中 116 例随机分配至复方新诺明组,118 例分配至头孢呋辛组。PEG 导管插入后 7-14 天随访时,复方新诺明组 10 例(8.6%)患者和头孢呋辛组 14 例(11.9%)患者出现伤口感染,百分比差异为-3.3%(95%置信区间-10.9%至 4.5%)。每组 100 例患者的方案分析结果相似,复方新诺明组和头孢呋辛组的感染率分别为 10%和 13%(百分比差异-3.0%,95%置信区间-11.8%至 5.8%)。这两种分析均表明复方新诺明与头孢呋辛相比不劣效,因为置信区间的上限低于预先确定的 15%非劣效性边界。次要结局分析支持这一发现。

结论

在接受 PEG 的患者中,将 20 毫升复方新诺明溶液注入新插入的 PEG 导管中,与 PEG 前静脉给予头孢呋辛相比,至少同样有效预防伤口感染。

试验注册

当前对照试验 ISRCTN85763161。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91e2/4787863/a1c67b5fa3cf/bloj747733.f1_default.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验